Un-audited financial results for the quarter and half year ended 30th September 2026

SUVEN® Life Sciences CSD/BM/SE/2026-27 Date: 5th November, 2026 To To Department of Corporate Services Listing Department BSE Limited National Stock Exchange of India Limited 25th Floor, P. J. Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai - 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 530239 Scrip Symbol: SUVEN Dear Sir/Madam, Sub: Outcome of Board Meeting Pursuant to the provisions of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is hereby informed that the Board of Directors of the Company, at its meeting held today i.e. November 5, 2026, has considered and approved Un-Audited Financial Results (Standalone and Consolidated) along with review reports of the Statutory Auditors for the quarter and half year ended 30th September, 2026. Enclosed herewith the following documents: - 1. The Un-Audited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2026 enclosed as Annexure 1 2. Limited Review Reports of Statutory Auditors of the Company enclosed as Annexure 2 3. News Release of the Company is enclosed as Annexure 3 Update on patents are available at: https://www.suven.com/Patentupdates.aspx The Board Meeting commenced at 12:00 Noon (IST) and concluded at 1:15 PM (IST). This is for your information and records. Thanking you. Yours faithfully, For Suven Life Sciences Limited K. Sangeetha Laxmi Company Secretary and Compliance officer Suven Life Sciences Limited Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor Road No.5 I Avenue 7 Banjara Hills I Hyderabad – 500 034 I Telangana I India I CIN: L24110TG1989PLC009713 Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com Annuexure - 1 ' SUVEN LIFE SCIENCES LIMITED Registered Office: 8-2-334, SOE Serene Chambers, 6th Floor, Road No. 5, Avenue 7, Banjara Hills, 500034, Telangana, India Tel: 91 40 2354 1142/ 1152 Email: investorservices@.suven.comWebsite:www.suven.com CIN: L24 l I0TG1989PLC009713 STATEMENT OF UN-AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & SIX MONTHS ENDED SEP'TEMBER 30, 2026 (Rs. in Lakhs, exce vt oer share data) STANDALONE Quarter Ended Six Months period ended Year Ended SI. No. PARTICULARS 30-Seo-2026 30-Jun-2026 30-Sep-2025 30-Seo-2026 30-Seo-2025 31-Mar-2026 UNAUDITED UN AUDITED UNAUDITED UNAUDITED UNAUDITED AUDITED 1 Income Revenue from operations 119.86 356.58 91.92 476.44 278. 59 711.47 Other Income 673.44 752.36 377.78 1,425.80 436.68 1,391.05 Total income 793.30 1,108.94 469.70 1,902.24 715.27 2,102.52 2 Expenses a) Cost of materials consumed - - . . - . b) Changes in inventories of finished goods, work-in- - - - . - . progress and stock-in-trade c) Employee benefits expense 718.96 728.18 607.65 1,447.14 1,205.21 2,414.94 d) Finance costs 45.76 47.61 . 93.37 - 15.78 e) Depreciation and amortisation expense 230.23 215.51 131.68 445.74 268.52 561.35 f) R & D Expenses 991.93 1,275.60 877.32 2,267.53 1,396.09 2,797.24 g) Other Expenses 444.55 453.95 397.56 898.50 867.83 1,799.49 Total expenses 2,431.43 2,720.85 2,014.21 5,152.28 3,737.65 7,588.80 3 Profit before exceptional items & Tax (1-2) (1,638.13) (1,611.91) (1,544.51) (3,250.04) (3,022.38) (5,486.28) 4 Exceptional Items - - - - - - 5 Profit before Tax (3-4) (1,638.13) (1,611.91) (1,544.51) (3,250.04) (3,022.38) (5,486.28) 6 Tax Expenses a) Current tax - - - - - - b) Deferred tax - - - - - - 7 Net Profit/ (Loss) for the period/ year(5-6) (1,638.13) (1,611.91) (1,544.51) (3,250.04) (3,022.38) (5,486.28) 8 Other Comprehensive Income 8.a (i) Items that will not be reclassified to profit or loss (5.54) (5.55) (1.50) (11.09) (3.00) (22.19) (ii) Income tax relating to items that will not be - - - - - - reclassified to orofit or loss 8.b (i) Items that will be reclassified to profit or loss - - - - - - (ii) Income tax relating to items that will be - - - - - - reclassified to nrofit or loss Total other Comprehensive Income (5.54) (5.55) (1.50) (11.09) (3.00) (22.19) 9 Total Comprehensive Income for the period (1,643.67) (1,617.46) (1,546.01) (3,261.13) (3,025.38) (5,508.47) Paid-up equity share capital 10 2,825.63 2,639.93 2,274.74 2,825.63 2,274.74 2,637.20 (Face Value of the Share Re.1.00 each) 11 Other Equity - - - - 1,47,699.51 12 Earning Per Share (EPS) (Face value of Rs. I/-each) a) Basic (0.58) (0.61) (0.70) (1.19) (1.36) (2.41) b) Diluted (0.58) (0.61) (0.70) (1.19) (1.36) (2.41) (not annualised) (not annualised) (not annualised) (not annualised) (not annualised) (annualised) (Rs. in Lakhs, excemt per share data) CONSOLIDATED Quarter Ended Six Months period ended Year Ended SI. No. PARTICULARS 30-Sep-2026 30-Jun-2026 30-Sep-2025 30-Sep-2026 30-Sep-2025 3I-Mar-2026 UN AUDITED UNAUDITED UNAUDITED UNAUDITED UNAUDITED AUDITED 1 Income Revenue from operations 119.86 356.58 91.92 476.44 278 . .:59 711.47 Other Income 673.44 752.36 377.80 1,425.80 437.78 1,393.01 Total income 793.30 1,108.94 469.72 1,902.24 716.37 2,104.48 2 Expenses a) Cost of materials consumed . . - . - - b) Changes in inventories of finished goods, work-in- - . - . - - progress and stock-in-trade c) Employee benefits expense 718.96 728.18 607.65 1,447.14 1,205.21 2,414.94 d) Finance costs 45.76 47.61 . 93.37 - 15.78 e) Depreciation and amortisation expense 230.23 215.51 131.68 445.74 268.52 561.35 f) R & D Expenses 10,029.99 12,383.10 7,032.13 22,413.09 11,180.97 24,818.8 I g) Other Expenses 462.57 495.57 429.25 958.14 944.35 1,928.01 Total expenses 11,487.51 13,869.97 8,200.71 25,357.48 13,599.05 29,738.89 3 Profit before exceptional items, Tax (1-2) (10,694.21) (12,761.03) (7,730.99) (23,455.24) (12,882.68) (27,634.41) 4 Exceptional Items . - - . - - 5 Profit before Tax (3-4) (10,694.21) (12,761.03) (7,730.99) (23,455.24) (12,882.68) (27,634.41) 6 Tax Expenses a) Current tax - - . - - - b) Deferred tax - - - - - - 7 Net Profit/ (Loss) for the period/ year(S-6) (10,694.21) (12,761.03) (7,730.99) (23,455.24) (12,882.68) (27,634.41) 8 Other Comprehensive Income 8.a (i) Items that will not be reclassified to profit or loss (5.54) (5.55) (1.50) (11.09) (3.00) (22.19) (ii) Income tax relating to items that will not be - . - - - - reclassified to profit or loss 8.b (i) Items that will be reclassified to profit or loss (17 .90) 1.95 10.02 (15.95) 6.40 (96.20) (ii) Income tax relating to items that will be - - - . - - reclassified to nrofit or loss Total other Comprehensive Income (23.44) (3.60) 8.52 (27.04) 3.40 (118.39) 9 Total Comprehensive Income for the period ( 7+ 8) (10,717.65) (12,764.63) (7,722.47) (23,482.28) (12,879.28) (27,752.80) Paid-up equity share capital IO 2,825.63 2,639.93 2,274.74 2,825.63 2,274.74 2,637.20 (Face Value of the Share Re. 1.00 each) 11 Other Equity - - - . - 56,502.76 12 Earning Per Share (EPS) (Face value of Rs.I/-each) a) Basic (3.77) (4.84) (3.48) (8.61) (5.80) (12.13) b) Diluted (3.77) (4.84) (3.48) (8.61) (5.80) (12.13) (not annualised) (not annualised) (not annualised) (not annualised) (not annualised) (annualised) NOTES:- 1) The above financial results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 05, 2026. The results for the quarter and six months ended September 30, 2026 has been reviewed by ours tatutory auditors. 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section I 33 of the Companies Act, 2013, read with relevant rules issued thereunder. 3) The consolidated financial results include the results of the two Wholly Owned Subsidiaries, Suven Neurosciences, Inc. and Suven :Neurosciences Pte. Ltd. (which was incorporated on 14 July 2026) and has been consolidated from that date. 4) The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS I 08 (Op [Showing first 8,000 characters — download PDF for full document]